Cited by 558Cervical Cancer and HPV ResearchWomen's cancer prevention and managementGlobal Cancer Incidence and Screening

Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis

Open access
Bruni, Laia, Serrano, Beatriz, Roura, Esther, Alemany, Laia, Cowan, Melanie, Herrero, Rolando, Poljak, Mario, Murillo, Raul +3 more·2022·The Lancet Global Health

Abstract

BACKGROUND: Cervical cancer screening coverage is a key monitoring indicator of the WHO cervical cancer elimination plan. We present global, regional, and national cervical screening coverage estimates against the backdrop of the 70% coverage target set by WHO. METHODS: In this review and synthetic analysis, we searched scientific literature, government websites, and official documentation to identify official national recommendations and coverage data for cervical cancer screening for the 194 WHO member states and eight associated countries and territories published from database inception until Oct 30, 2020, supplemented with a formal WHO country consultation from Nov 27, 2020, to Feb 12, 2021. We extracted data on the year of introduction of recommendations, the existence of individual invitation to participate, financing of screening tests, primary screening and triage tests used, recommended ages and screening intervals, use of self-sampling, and use of screen-and-treat approaches. We also collected coverage data, either administrative or survey-based, as disaggregated as possible by age and for any available screening interval. According to data completeness and representativeness, different statistical models were developed to produce national age-specific coverages by screening interval, which were transformed into single-age datapoints. Missing data were imputed. Estimates were applied to the 2019 population and aggregated by region and income level. FINDINGS: We identified recommendations for cervical screening in 139 (69%) of 202 countries and territories. Cytology was the primary screening test in 109 (78%) of 139 countries. 48 (35%) of 139 countries recommended primary HPV-based screening. Visual inspection with acetic acid was the most recommended test in resource-limited settings. Estimated worldwide coverage in women aged 30-49 years in 2019 was 15% in the previous year, 28% in the previous 3 years, and 32% in the previous 5 years, and 36% ever in lifetime. An estimated 1·6 billion (67%) of 2·3 billion women aged 20-70 years, including 662 million (64%) of 1·0 billion women aged 30-49 years, had never been screened for cervical cancer. 133 million (84%) of 158 million women aged 30-49 years living in high-income countries had been screened ever in lifetime, compared with 194 million (48%) of 404 million women in upper-middle-income countries, 34 million (9%) of 397 million women in lower-middle-income countries, and 8 million (11%) of 74 million in low-income countries. INTERPRETATION: Two in three women aged 30-49 years have never been screened for cervical cancer. Roll-out of screening is very low in low-income and middle-income countries, where the burden of disease is highest. The priority of the WHO elimination campaign should be to increase both screening coverage and treatment of detected lesions; however, expanding the efforts of surveillance systems in both coverage and quality control are major challenges to achieving the WHO elimination target. FUNDING: Instituto de Salud Carlos III, European Regional Development Fund, Secretariat for Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and Horizon 2020. TRANSLATIONS: For the French, Spanish translations of the abstract see Supplementary Materials section.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2214-109x(22)00241-8

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Initial cervical screening is most commonly recommended to 25-29 year olds across high- and low-income countries.

    “initial cervical screening is most commonly recommended to 25–29 year olds, across both high- and low-income countries 18”

    From Identifying the key barriers, facilitators and factors associated with cervical cancer screening attendance in young women: A systematic review (2025) · cites this paper as [18]

    The Results report that 25–29 years was the most common starting-age range overall (55 of 139 countries). But the Results table does not support that pattern in both income groups: high-income countries more often recommended starting at 24 or younger (28 versus 23), and low-income countries more often recommended 30–34 (6 versus 4). (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • In India, access to preventive measures for cervical cancer, including HPV vaccination and cervical cancer screening, remains low.

    “Despite the high burden of cervical cancer, access to preventive measures remains low in India.”

    From Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study (2022) · cites this paper as [8]

    The Discussion (page unavailable) reports that fewer than 3% of women aged 30–49 in India had ever been screened in a 2017–18 survey, supporting low access to cervical cancer screening. The paper does not establish that access to HPV vaccination in India is also low, so it supports only part of the attributed claim. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Access to cervical cancer screening in India is very low.

    “Because access to cervical cancer screening in India is very low, we assumed no screening throughout all scenarios.8”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 21

  1. [1]Arbyn M Weiderpass E Bruni L Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis Lancet Glob Health 8 2020 e191 e203 31812369 PMC7025157
  2. [2]Vaccarella S Lortet-Tieulent J Saracci R Conway DI Straif K Wild CP Reducing social inequalities in cancer: evidence and priorities for research 2019 International Agency for Research on Cancer Lyon, France 33443989
  3. [5]Arbyn M Ronco G Anttila A Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer Vaccine 30 suppl 5 2012 F88 F99 23199969
  4. [9]Maver PJ Poljak M Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans Clin Microbiol Infect 26 2020 579 583 31539637
  5. [10]Gravitt PE Silver MI Hussey HM Achieving equity in cervical cancer screening in low- and middle-income countries (LMICs): Strengthening health systems using a systems thinking approach Prev Med 144 2021 106322 PMC12961690 33678230
  6. [11]Arbyn M Simon M Peeters E 2020 list of human papillomavirus assays suitable for primary cervical cancer screening Clin Microbiol Infect 27 2021 1083 1095 33975008
  7. [12]Poljak M Oštrbenk Valenčak A Gimpelj Domjanič G Xu L Arbyn M Commercially available molecular tests for human papillomaviruses: a global overview Clin Microbiol Infect 26 2020 1144 1150 32247892
  8. [15]Stevens GA Alkema L Black RE Guidelines for accurate and transparent health estimates reporting: the GATHER statement Lancet 388 2016 e19 e23 27371184
  9. [18]Holme F Kapambwe S Nessa A Basu P Murillo R Jeronimo J Scaling up proven innovative cervical cancer screening strategies: challenges and opportunities in implementation at the population level in low- and lower-middle-income countries Int J Gynaecol Obstet 138 suppl 1 2017 63 68 28691331
  10. [19]Canfell K Kim JJ Brisson M Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries Lancet 395 2020 591 603 32007142 PMC7043006
  11. [22]Poljak M Seme K Maver PJ Human papillomavirus prevalence and type-distribution, crvical cancer screening practices and current status of vaccination implementation in central and eastern Europe Vaccine 31 suppl 7 2013 H59 H70 24332298
  12. [23]Ryzhov A Corbex M Piñeros M Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study Lancet Oncol 22 2021 361 369 33556324 PMC8014987
  13. [24]Goss PE Lee BL Badovinac-Crnjevic T Planning cancer control in Latin America and the Caribbean Lancet Oncol 14 2013 391 436 23628188
  14. [25]Lopez MS Baker ES Maza M Cervical cancer prevention and treatment in Latin America J Surg Oncol 115 2017 615 618 28168717 PMC5990960
  15. [26]Bosch FX Seoud M Garland SM Albero G Lamontagne DS Comprehensive control of HPV infections and related diseases in the extended Middle East and north Africa Region Vaccine 31 suppl 6 2013 G1 82 24331818
  16. [27]Woo YL Gravitt P Khor SK Ng CW Saville M Accelerating action on cervical screening in lower- and middle-income countries (LMICs) post COVID-19 era Prev Med 144 2021 106294 PMC7931730 33678225
  17. [29]Rabeneck L Saraiya M COVID-19 and the disruption of cancer screening programs: key lessons for the recovery Prev Med 151 2021 106687 PMC8241685 34217408
  18. [30]Wentzensen N Clarke MA Perkins RB Impact of COVID-19 on cervical cancer screening: challenges and opportunities to improving resilience and reduce disparities Prev Med 151 2021 106596 PMC8241689 34217415
  19. [31]Arbyn M Bruni L Kelly D Tackling cervical cancer in Europe amidst the COVID-19 pandemic Lancet Public Health 5 2020 e425 32673570 PMC7357980
  20. [32]Gakidou E Nordhagen S Obermeyer Z Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities PLoS Med 5 2008 e132 18563963 PMC2429949
  21. [34]Howard M Agarwal G Lytwyn A Accuracy of self-reports of Pap and mammography screening compared to medical record: a meta-analysis Cancer Causes Control 20 2009 1 13 18802779

Cited by

Sorted by citations

Authors
Bruni, L., Serrano, B., Roura, E., Alemany, L., Cowan, M., Herrero, R., Poljak, M., Murillo, R., Broutet, N., Riley, L. M., & de Sanjose, S.
Affiliations
  • Institut Català d'Oncologia (ES)
  • World Health Organization (CH)
  • Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud (CR)
  • University of Ljubljana (SI)
Corresponding author
Bruni, Laia
Venue
The Lancet Global Health
Publisher
Elsevier BV
Published
2022-08
Volume
10
Issue
8
Pages
e1115-e1127
ISSN
2214-109X (ISSN-L)
OpenAlex
W4285082442
Cited by
558
References
4
Citations by year
2026: 128 · 2025: 166 · 2024: 147 · 2023: 106 · 2022: 11
FWCI
77.79
Type
journal article
Language
en
Update notices
erratum (2023-07-01)
Open access
Locations
  • The Lancet Global Health (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Repositorio Institucional (Pontificia Universidad Javeriana) (publishedVersion, cc-by-nc)
Funders
  • European Commission
  • Generalitat de Catalunya (SGR 2017–2019)
  • Instituto de Salud Carlos III (PI18/01137)
  • Horizon 2020 (847845)
  • European Regional Development Fund
  • Government of Catalonia Department of Business and Knowledge (2017SGR1085, 2017SGR1718)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Keywords
cervical cancer screening, screening coverage, cervical cancer elimination, HPV-based screening, cytology, visual inspection with acetic acid, self-sampling, screen-and-treat, screening guidelines, screening frequency, low-income settings, high-income settings, global health disparities, synthetic analysis, cervical cancer incidence and mortality, cervical cancer prevention
MeSH terms
Age Factors, Uterine Cervical Neoplasms, Female, Humans, Mass Screening, Papillomavirus Infections, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review